The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: sub-study of the HERO trial.

Zhang, Lei, Coombes, Jeff, Pascoe, Elaine M., Badve, Sunil V., Dalziel, Kim, Cass, Alan, Clarke, Philip, FerrarI, Paolo, McDonald, Stephen P., Morrish, Alicia T., Pedagogos, Eugenie, Perkovic, Vlado, Reidlinger, Donna, Scaria, Anish, Walker, Rowan, Vergara, Liza A., Hawley, Carmel M. and Johnson, David W. (2016) The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: sub-study of the HERO trial.. Redox Report, 21 1: 14-23. doi:10.1179/1351000215Y.0000000022


Author Zhang, Lei
Coombes, Jeff
Pascoe, Elaine M.
Badve, Sunil V.
Dalziel, Kim
Cass, Alan
Clarke, Philip
FerrarI, Paolo
McDonald, Stephen P.
Morrish, Alicia T.
Pedagogos, Eugenie
Perkovic, Vlado
Reidlinger, Donna
Scaria, Anish
Walker, Rowan
Vergara, Liza A.
Hawley, Carmel M.
Johnson, David W.
Title The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: sub-study of the HERO trial.
Journal name Redox Report   Check publisher's open access policy
ISSN 1351-0002
1743-2928
Publication date 2016
Sub-type Article (original research)
DOI 10.1179/1351000215Y.0000000022
Open Access Status Not Open Access
Volume 21
Issue 1
Start page 14
End page 23
Total pages 10
Place of publication Leeds, W Yorks, United Kingdom
Publisher Maney Publishing
Collection year 2017
Language eng
Formatted abstract
Objective:  Pentoxifylline has previously been shown to increase haemoglobin levels in patients with chronic kidney disease (CKD) and erythropoietin-stimulating agent (ESA)-hyporesponsive anaemia in the HERO multi-centre double-blind, randomized controlled trial. The present study evaluated the effects of pentoxifylline on oxidative stress in ESA-hyporesponsive CKD patients.

Methods:  This sub-study of the HERO trial compared 15 patients in the pentoxifylline arm (400 mg daily) and 17 in the matched placebo arm on oxidative stress markers: plasma total F2-isoprostanes, protein carbonyls, glutathione peroxidase (GPX), and superoxide dismutase (SOD) activities.

Results:  Pentoxifylline did not significantly alter total F2-isoprostanes (adjusted mean difference (MD) 35.01 pg/ml, P = 0.11), SOD activity (MD 0.82 U/ml, P = 0.07), GPX activity (MD −6.06 U/l, P = 0.09), or protein carbonyls (MD −0.04 nmol/mg, P = 0.52). Replicating results from the main study, pentoxifylline significantly increased haemoglobin concentration compared with controls (MD 7.2 g/l, P = 0.04).

Conclusions:  Pentoxifylline did not alter oxidative stress biomarkers, suggesting that alternative mechanisms may be responsible for the agent's ability to augment haemoglobin levels in CKD patients with ESA-hyporesponsive anaemia.
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status UQ

 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 1 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 0 times in Scopus Article
Google Scholar Search Google Scholar
Created: Mon, 08 Feb 2016, 09:43:17 EST by Sandrine Ducrot on behalf of School of Human Movement and Nutrition Sciences